G Arnaldi
Overview
Explore the profile of G Arnaldi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnaldi G, Arvat E, Berton A, Corona G, Faustini Fustini M, Ferrante E, et al.
J Endocrinol Invest
. 2023 Jul;
46(12):2453-2457.
PMID: 37452912
No abstract available.
2.
Martino M, Aboud N, Cola M, Giancola G, Ciarloni A, Salvio G, et al.
J Endocrinol Invest
. 2020 Sep;
44(5):1075-1084.
PMID: 32946078
Purpose: COVID-19 is a novel threat to patients with adrenal insufficiency (AI), whose life expectancy and quality (QoL) are impaired by an increased risk of infections and stress-triggered adrenal crises...
3.
Arosio M, Arnaldi G, Gasco V, Giavoli C, Puxeddu E, Vettor R, et al.
J Endocrinol Invest
. 2020 Jun;
44(2):327-337.
PMID: 32507990
Purpose: PATRO adults is an ongoing, multicenter, observational, post-marketing surveillance study aimed at investigating the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the recombinant human growth hormone (rhGH)...
4.
Isidori A, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al.
J Endocrinol Invest
. 2020 Apr;
43(8):1141-1147.
PMID: 32335855
No abstract available.
5.
Isidori A, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al.
J Endocrinol Invest
. 2019 Nov;
43(5):683-696.
PMID: 31773582
Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice....
6.
Minetto M, Caresio C, Salvi M, DAngelo V, Gorji N, Molinari F, et al.
J Endocrinol Invest
. 2018 Nov;
42(7):757-768.
PMID: 30443856
Purpose: To investigate the glucocorticoid-induced impairments of muscle mass and structure in patients presenting different stages of steroid myopathy progression. Methods: Thirty-three patients (28 women) affected by active (N = ...
7.
Ceccato F, Marcelli G, Martino M, Concettoni C, Brugia M, Trementino L, et al.
J Endocrinol Invest
. 2018 Jul;
42(3):327-335.
PMID: 29987756
Introduction And Aim: A prompt diagnosis of Cushing's Syndrome (CS) in high-risk populations is mandatory: 1-mg dexamethasone suppression test (1-mg DST), late night salivary cortisol (LNSC), and urinary-free cortisol (UFC)...
8.
Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, et al.
J Endocrinol Invest
. 2017 Dec;
41(2):267.
PMID: 29285678
Unfortunately, in page 584, second column, the first sentence under the heading "Type of switch" has been published incorrectly. The complete correct sentence is given below.
9.
Caffarini M, Orciani M, Trementino L, Di Primio R, Arnaldi G
J Endocrinol Invest
. 2017 Dec;
41(7):745-753.
PMID: 29222642
Purpose: To clarify the existence of pituitary stem cells (SCs) both in the embryonic and the postnatal gland and the role for SCs in pituitary adenomas. Methods: This work, which...
10.
Sbardella E, Isidori A, Arnaldi G, Arosio M, Barone C, Benso A, et al.
J Endocrinol Invest
. 2017 Nov;
41(1):3-19.
PMID: 29152673
No abstract available.